| Q42203233 | ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia |
| Q27852067 | Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. |
| Q91565663 | Acute lymphoblastic leukaemia |
| Q38806478 | Adolescent and young adult non-Hodgkin lymphoma. |
| Q37681450 | Adult acute lymphoblastic leukemia: concepts and strategies |
| Q36508630 | Advances in paediatric cancer treatment |
| Q47113632 | Advances in the understanding and management of T-cell prolymphocytic leukemia |
| Q38603452 | Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis |
| Q26781328 | Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia |
| Q37847484 | Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance |
| Q34764504 | Biology, risk stratification, and therapy of pediatric acute leukemias: an update |
| Q37257126 | Bone-marrow relapse in paediatric acute lymphoblastic leukaemia |
| Q28080463 | Childhood acute lymphoblastic leukemia: Integrating genomics into therapy |
| Q38822525 | Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science |
| Q33711119 | Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia |
| Q29617588 | Chimeric antigen receptor T cells for sustained remissions in leukemia |
| Q36771221 | Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin |
| Q38368591 | Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication |
| Q36731404 | Clofarabine for the treatment of acute lymphoblastic leukemia |
| Q37424784 | Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. |
| Q37824438 | Educational paper. The development of new therapies for pediatric oncology |
| Q36758604 | Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia |
| Q51542169 | Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma. |
| Q53657116 | Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children. |
| Q92122315 | High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia |
| Q46294823 | Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma |
| Q35989408 | Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group |
| Q57284581 | Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization |
| Q37360025 | Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway |
| Q36508149 | Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy |
| Q47137669 | Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials |
| Q50561292 | Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study |
| Q44027017 | Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine |
| Q35667279 | Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies |
| Q34469099 | Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients |
| Q38102065 | Lymphoblastic lymphoma in childhood and adolescence |
| Q38371659 | Management of Non-Hodgkin Lymphoma: ICMR Consensus Document. |
| Q34010279 | Nelarabine |
| Q82585791 | Nelarabine |
| Q41847188 | Nelarabine associated myotoxicity and rhabdomyolysis |
| Q30240892 | Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma |
| Q24569660 | Nelarabine in the treatment of refractory T-cell malignancies |
| Q34559575 | Nelarabine in the treatment of refractory T-cell malignant diseases |
| Q33374461 | Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. |
| Q38198998 | Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature |
| Q50168849 | Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater? |
| Q53333607 | Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. |
| Q48091595 | Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history? |
| Q36572507 | Nelarabine: efficacy in the treatment of clinical malignancies |
| Q30448951 | Neurological adverse effects caused by cytotoxic and targeted therapies. |
| Q48298283 | Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy |
| Q84122235 | New agents for the treatment of patients with acute lymphoblastic leukemia |
| Q36284664 | New agents in the treatment of childhood leukemias and myelodysplastic syndromes |
| Q37854715 | New drug therapies in peripheral T-cell lymphoma |
| Q37841589 | New nucleoside analogs for patients with hematological malignancies |
| Q36724661 | New therapeutic strategies for the treatment of acute lymphoblastic leukaemia |
| Q36654341 | Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma |
| Q39824851 | Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group |
| Q41942675 | Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. |
| Q38097334 | Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions |
| Q37851951 | Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults |
| Q37048013 | Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency |
| Q30417943 | Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group |
| Q33916091 | Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia |
| Q35615374 | Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder |
| Q24633723 | Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia |
| Q89286746 | Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia |
| Q38025789 | Recent advances in the understanding and treatment of pediatric leukemias |
| Q61953181 | Relapsed Acute Lymphoblastic Leukemia of Childhood |
| Q37301312 | Relapsed acute lymphoblastic leukemia: current status and future opportunities |
| Q38103645 | Relapsed childhood acute lymphoblastic leukaemia |
| Q39869982 | Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols |
| Q38033592 | Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments |
| Q97545576 | Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant |
| Q34592646 | Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. |
| Q96683744 | SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine |
| Q30300395 | Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434 |
| Q38644266 | Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study |
| Q53971707 | Severe, reversible nelarabine-induced neuropathy and myelopathy. |
| Q92941579 | Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia |
| Q30240217 | T-cell acute lymphoblastic leukemia. |
| Q26746934 | Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future |
| Q90413960 | The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects |
| Q54699874 | The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. |
| Q37271941 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years |
| Q30243925 | Treating adults with acute lymphocytic leukemia: new pharmacotherapy options |
| Q37932546 | Treatment algorithms for mature T-cell and natural killer-cell neoplasms |
| Q36967160 | Treatment of acute lymphoblastic leukaemia : a new era. |
| Q35196702 | Treatment of pediatric acute lymphoblastic leukemia |
| Q36521840 | Update on the therapy of highly aggressive non-Hodgkin's lymphoma |